Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. on January 10, 2020, reporting events occurring between January 9, 2020, and January 15, 2020. The company is an emerging growth company incorporated in Delaware with principal executive offices in Melville, New York. The filing details unregistered sales of equity securities and significant changes to executive compensation.
Key Financial Metrics and Capital Activities
- Debt-for-Equity Exchange: Issued 71,247,641 shares of common stock to settle outstanding indebtedness totaling $186,914 (including accrued interest).
- Equity Financing: Issued 1,000,000 shares of common stock and a five-year warrant for 1,000,000 shares (exercise price $0.015) for gross proceeds of $10,000.
- Debt Financing: Issued a convertible promissory note with a principal of $88,000 for cash proceeds of $85,000. The note bears 12% annual interest, matures in January 2021, and is convertible at 61% of fair market value after six months.
- Liquidity and Margins: The filing text does not provide clear values for revenue, net profit, operating margins, or overall liquidity positions.
Material Changes and Executive Compensation
Effective January 15, 2020, the Company implemented salary reductions for key officers to conserve cash. The new annual salaries are as follows:
- Mark Weinreb (CEO/President/Chairman): Reduced to $46,800.
- Lance Alstodt (EVP/Chief Strategy Officer): Reduced to $46,800.
- Francisco Silva (VP of R&D): Reduced to $46,800.
- Robert Paccasassi (VP of Quality and Compliance): Reduced to $140,875.
- Mandy Clyde (VP of Operations): Reduced to $104,633.
These reductions do not affect severance entitlements under existing employment agreements.
Outlook, Risks, and Unusual Items
The Company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 for the unregistered securities offerings, asserting that investors were accredited and had access to financial information. The issuance of a high-interest convertible note with a significant discount (61% conversion price) suggests potential liquidity constraints and dilution risks for existing shareholders. The filing does not contain specific forward-looking guidance or management commentary regarding future operational milestones.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess the dilution impact of the 72.2 million shares issued for debt and equity.
- Confirm the Company's current cash runway given the reliance on debt-for-equity swaps and high-interest convertible notes.
- Review the terms of the convertible note to understand the potential future share issuance if the holder elects conversion.
- Assess the impact of executive salary reductions on operational stability and employee retention.